|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonnomet A, Brysse A, Tachsidis A, Waltham
M, Thompson EW, Polette M and Gilles C: Epithelial-to-mesenchymal
transitions and circulating tumor cells. J Mammary Gland Biol
Neoplasia. 15:261–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kapuria V, Peterson LF, Fang D, Bornmann
WG, Talpaz M and Donato NJ: Deubiquitinase inhibition by
small-molecule WP1130 triggers aggresome formation and tumor cell
apoptosis. Cancer Res. 70:9265–9276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kerscher O, Felberbaum R and Hochstrasser
M: Modification of proteins by ubiquitin and ubiquitin-like
proteins. Annu Rev Cell Dev Biol. 22:159–180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hussain S, Zhang Y and Galardy PJ: DUBs
and cancer: The role of deubiquitinating enzymes as oncogenes,
non-oncogenes and tumor suppressors. Cell Cycle. 8:1688–1697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reyes-Turcu FE, Ventii KH and Wilkinson
KD: Regulation and cellular roles of ubiquitin-specific
deubiquitinating enzymes. Annu Rev Biochem. 78:363–397. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schwickart M, Huang X, Lill JR, Liu J,
Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F,
Eastham-Anderson J, et al: Deubiquitinase USP9X stabilizes MCL1 and
promotes tumour cell survival. Nature. 463:103–107. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harris DR, Mims A and Bunz F: Genetic
disruption of USP9X sensitizes colorectal cancer cells to
5-fluorouracil. Cancer Biol Ther. 13:1319–1324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H, Chen W, Liang C, Chen BW, Zhi X,
Zhang S, Zheng X, Bai X and Liang T: WP1130 increases doxorubicin
sensitivity in hepatocellular carcinoma cells through
usp9×-dependent p53 degradation. Cancer Lett. 361:218–225. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cox JL, Wilder PJ, Wuebben EL, Ouellette
MM, Hollingsworth MA and Rizzino A: Context-dependent function of
the deubiquitinating enzyme USP9X in pancreatic ductal
adenocarcinoma. Cancer Biol Ther. 15:1042–1052. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pérez-Mancera PA, Rust AG, van der Weyden
L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R,
Aust D, Rümmele P, et al: Australian Pancreatic Cancer Genome
Initiative: The deubiquitinase USP9X suppresses pancreatic ductal
adenocarcinoma. Nature. 486:266–270. 2012.PubMed/NCBI
|
|
13
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smith BN and Odero-Marah VA: The role of
Snail in prostate cancer. Cell Adhes Migr. 6:433–441. 2012.
View Article : Google Scholar
|
|
17
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roca H, Varsos ZS, Mizutani K and Pienta
KJ: CCL2, survivin and autophagy: New links with implications in
human cancer. Autophagy. 4:969–971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Farnebo L, Tiefenböck K, Ansell A, Thunell
LK, Garvin S and Roberg K: Strong expression of survivin is
associated with positive response to radiotherapy and improved
overall survival in head and neck squamous cell carcinoma patients.
Int J Cancer. 133:1994–2003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu YB, Gao X, Deeb D, Brigolin C, Zhang
Y, Shaw J, Pindolia K and Gautam SC: Ubiquitin-proteasomal
degradation of antiapoptotic survivin facilitates induction of
apoptosis in prostate cancer cells by pristimerin. Int J Oncol.
45:1735–1741. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng J, Hu Q, Liu W, He X, Cui L, Chen X,
Yang M, Liu H, Wei W, Liu S, et al: USP9X expression correlates
with tumor progression and poor prognosis in esophageal squamous
cell carcinoma. Diagn Pathol. 8:177–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ahmad R: Cheema, Eileen M. O'Reilly.
Management of metastatic pancreatic adenocarcinoma. Surg Clin North
Am. 7:1391–1414. 2016.
|
|
23
|
Murtaza M, Jolly LA, Gecz J and Wood SA:
La FAM fatale: USP9X in development and disease. Cell Mol Life Sci.
72:2075–2089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Liu Y, Yang B, Cao H, Yang CX,
Ouyang W, Zhang SM, Yang GF, Zhou FX, Zhou YF, et al: Elevated
expression of USP9X correlates with poor prognosis in human
non-small cell lung cancer. J Thorac Dis. 7:672–679.
2015.PubMed/NCBI
|
|
25
|
Vermeulen L, Todaro M, de Sousa Mello F,
Sprick MR, Kemper K, Alea Perez M, Richel DJ, Stassi G and Medema
JP: Single-cell cloning of colon cancer stem cells reveals a
multi-lineage differentiation capacity. Proc Natl Acad Sci USA.
105:13427–13432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Findlay VJ, Wang C, Watson DK and Camp ER:
Epithelial-to-mesenchymal transition and the cancer stem cell
phenotype: Insights from cancer biology with therapeutic
implications for colorectal cancer. Cancer Gene Ther. 21:181–187.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
von Burstin J, Eser S, Paul MC, Seidler B,
Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, et
al: E-cadherin regulates metastasis of pancreatic cancer in vivo
and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
Gastroentemlogy. 137:361–371. 2009. View Article : Google Scholar
|
|
28
|
Lang SH, Hyde C, Reid IN, Hitchcock IS,
Hart CA, Bryden AA, Villette JM, Stower MJ and Maitland NJ:
Enhanced expression of vimentin in motile prostate cell lines and
in poorly differentiated and metastatic prostate carcinoma.
Prostate. 52:253–263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee MY, Chou CY, Tang MJ and Shen MR:
Epithelial-mesenchymal transition in cervical cancer: Correlation
with tumor progression, epidermal growth factor receptor
overexpression, and snail up-regulation. Clin Cancer Res.
14:4743–4750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Francí C, Takkunen M, Dave N, Alameda F,
Gómez S, Rodríguez R, Escrivà M, Montserrat-Sentís B, Baró T,
Garrido M, et al: Expression of Snail protein in tumor-stroma
interface. Oncogene. 25:5134–5144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu JH, Wang AX, Huang HZ, Wang JG, Pan CB
and Zhang B: Survivin shRNA induces caspase-3-dependent apoptosis
and enhances cisplatin sensitivity in squamous cell carcinoma of
the tongue. Oncol Res. 18:377–385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lopes RB, Gangeswaran R, McNeish IA, Wang
Y and Lemoine NR: Expression of the IAP protein family is
dysregulated in pancreatic cancer cells and is important for
resistance to chemotherapy. Int J Cancer. 120:2344–2352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jhala N, Jhala D, Vickers SM, Eltoum I,
Batra SK, Manne U, Eloubeidi M, Jones JJ and Grizzle WE: Biomarkers
in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J
Clin Pathol. 126:572–579. 2006. View Article : Google Scholar : PubMed/NCBI
|
